Arcutis Biotherapeutics Inc. | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 65.8M
Gross Profit 57.0M 86.59%
Operating Income -24.5M -37.25%
Net Income -25.1M -38.06%
EPS (Diluted) $-0.20

Balance Sheet Metrics

Total Assets 344.1M
Total Liabilities 201.4M
Shareholders Equity 142.7M
Debt to Equity 1.41

Cash Flow Metrics

Operating Cash Flow -25.8M
Free Cash Flow -31.0M

Revenue & Profitability Trend

Arcutis Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i196.5M59.6M3.7M00
Cost of Goods Sold i19.1M5.0M754.0K00
Gross Profit i177.4M54.6M2.9M00
Gross Margin % i90.3%91.6%79.5%0.0%0.0%
Operating Expenses
Research & Development i76.4M110.6M182.4M145.6M115.3M
Selling, General & Administrative i229.4M185.1M122.1M61.0M21.3M
Other Operating Expenses i-----
Total Operating Expenses i305.8M295.7M304.6M206.5M136.6M
Operating Income i-128.4M-241.1M-301.6M-206.5M-136.6M
Operating Margin % i-65.3%-404.5%-8,183.0%0.0%0.0%
Non-Operating Items
Interest Income i-----
Interest Expense i27.2M29.7M15.7M00
Other Non-Operating Income16.2M11.8M5.8M173.0K967.0K
Pre-tax Income i-139.4M-259.0M-311.5M-206.4M-135.7M
Income Tax i647.0K3.1M00-
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-140.0M-262.1M-311.5M-206.4M-135.7M
Net Margin % i-71.3%-439.8%-8,449.8%0.0%0.0%
Key Metrics
EBITDA i-109.6M-227.8M-294.9M-205.9M-135.6M
EPS (Basic) i$-1.16$-3.78$-5.66$-4.18$-3.80
EPS (Diluted) i$-1.16$-3.78$-5.66$-4.18$-3.80
Basic Shares Outstanding i12095763369305487550322654940557535668152
Diluted Shares Outstanding i12095763369305487550322654940557535668152

Income Statement Trend

Arcutis Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i71.3M88.4M53.6M96.4M65.1M
Short-term Investments i156.6M183.5M355.9M290.6M219.4M
Accounts Receivable i73.1M25.8M8.5M0-
Inventory i14.5M13.1M7.5M0-
Other Current Assets8.2M8.2M6.3M8.0M-
Total Current Assets i335.8M330.4M437.4M402.8M292.8M
Non-Current Assets
Property, Plant & Equipment i2.0M2.4M2.7M3.0M3.3M
Goodwill i9.5M6.4M7.2M0-
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets596.0K596.0K78.0K78.0K78.0K
Total Non-Current Assets i13.1M10.9M11.9M5.4M5.4M
Total Assets i348.9M341.4M449.3M408.2M298.3M
Liabilities
Current Liabilities
Accounts Payable i14.2M12.0M8.8M7.4M7.1M
Short-term Debt i820.0K735.0K657.0K433.0K-
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i81.0M46.7M37.8M33.3M22.6M
Non-Current Liabilities
Long-term Debt i109.8M205.2M201.9M77.1M5.0M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities570.0K849.0K-25.0K82.0K
Total Non-Current Liabilities i110.3M206.0M201.9M77.1M5.0M
Total Liabilities i191.3M252.7M239.7M110.5M27.6M
Equity
Common Stock i12.0K9.0K6.0K5.0K4.0K
Retained Earnings i-1.1B-981.9M-719.8M-408.3M-202.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i157.5M88.7M209.6M297.7M270.6M
Key Metrics
Total Debt i110.6M205.9M202.5M77.6M5.0M
Working Capital i254.8M283.8M399.6M369.4M270.2M

Balance Sheet Composition

Arcutis Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-140.0M-262.1M-311.5M-206.4M-135.7M
Depreciation & Amortization i2.6M1.5M934.0K454.0K122.0K
Stock-Based Compensation i41.7M38.8M32.7M23.9M7.9M
Working Capital Changes i-46.2M-20.5M-14.8M488.0K5.7M
Operating Cash Flow i-136.1M-237.9M-260.1M-181.2M-121.6M
Investing Activities
Capital Expenditures i-143.0K-428.0K-333.0K-995.0K-321.0K
Acquisitions i-----
Investment Purchases i-254.8M-225.8M-415.4M-292.5M-279.1M
Investment Sales i288.8M406.5M351.5M217.6M97.6M
Investing Cash Flow i33.8M180.2M-64.2M-76.0M-181.8M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i00125.0M74.0M0
Debt Repayment i-100.0M----
Financing Cash Flow i61.7M98.9M298.9M279.8M297.0M
Free Cash Flow i-117.3M-247.5M-281.0M-175.6M-113.4M
Net Change in Cash i-40.6M41.2M-25.5M22.7M-6.4M

Cash Flow Trend

Arcutis Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -13.78
Forward P/E -16.31
Price to Book 13.78
Price to Sales 7.27
PEG Ratio 0.20

Profitability Ratios

Profit Margin -35.40%
Operating Margin -17.93%
Return on Equity -57.33%
Return on Assets -13.46%

Financial Health

Current Ratio 3.20
Debt to Equity 79.27
Beta 1.84

Per Share Data

EPS (TTM) $-0.73
Book Value per Share $1.16
Revenue per Share $2.10

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
arqt1.9B-13.7813.78-57.33%-35.40%79.27
Vertex 101.3B28.085.9022.77%31.86%8.89
Regeneron 63.6B15.122.0915.34%31.37%9.04
Sarepta Therapeutics 2.0B19.981.46-4.76%-2.34%100.51
Adaptive 1.9B-12.0410.69-57.60%-59.07%121.39
ProKidney 1.8B-3.890.93-40.52%0.00%1.30

Financial data is updated regularly. All figures are in the company's reporting currency.